A61K36/287

PLANT EXTRACT MIXTURE FOR USE IN THE PREVENTION AND/OR TREATMENT OF CHRONIC INFLAMMATORY BOWEL DISEASES
20220257685 · 2022-08-18 ·

The invention relates to a composition comprising at least: an extract of Chrysanthellum, and an extract of artichoke, and an extract of blueberry, and an extract of at least one plant-derived raw material comprising oleuropein, and optionally synthetic piperine and/or an extract of at least one plant-derived raw material comprising piperine,
for use as a drug or nutritional product in the prevention and/or treatment of chronic inflammatory bowel disease in humans or animals.

PLANT EXTRACT MIXTURE FOR USE IN THE PREVENTION AND/OR TREATMENT OF CHRONIC INFLAMMATORY BOWEL DISEASES
20220257685 · 2022-08-18 ·

The invention relates to a composition comprising at least: an extract of Chrysanthellum, and an extract of artichoke, and an extract of blueberry, and an extract of at least one plant-derived raw material comprising oleuropein, and optionally synthetic piperine and/or an extract of at least one plant-derived raw material comprising piperine,
for use as a drug or nutritional product in the prevention and/or treatment of chronic inflammatory bowel disease in humans or animals.

COMPOSITION FOR AMELIORATING PREMENSTRUAL SYNDROME SYMPTOMS, INCLUDING CHRYSANTHEMUM ZAWADSKII EXTRACT

The present invention relates to a composition which is for preventing and ameliorating or treating premenstrual syndrome symptoms, and includes: (a) a Chrysanthemum zawadskii extract; (b) a mixture of the Chrysanthemum zawadskii extract and a malt extract; or (c) a mixture of the Chrysanthemum zawadskii extract, the malt extract, and an aloe extract. Specifically, the present compositions effectively inhibit the secretion of prolactin from pituitary cells, which is a phenomenon that appears during premenstrual syndrome, thereby increasing the secretion of progesterone, which is reduced during the luteal phase of women, and can thus be advantageously used as a composition for preventing and ameliorating or treating women's premenstrual syndrome.

COMPOSITION FOR AMELIORATING PREMENSTRUAL SYNDROME SYMPTOMS, INCLUDING CHRYSANTHEMUM ZAWADSKII EXTRACT

The present invention relates to a composition which is for preventing and ameliorating or treating premenstrual syndrome symptoms, and includes: (a) a Chrysanthemum zawadskii extract; (b) a mixture of the Chrysanthemum zawadskii extract and a malt extract; or (c) a mixture of the Chrysanthemum zawadskii extract, the malt extract, and an aloe extract. Specifically, the present compositions effectively inhibit the secretion of prolactin from pituitary cells, which is a phenomenon that appears during premenstrual syndrome, thereby increasing the secretion of progesterone, which is reduced during the luteal phase of women, and can thus be advantageously used as a composition for preventing and ameliorating or treating women's premenstrual syndrome.

COMPOSITION FOR AMELIORATING PREMENSTRUAL SYNDROME SYMPTOMS, INCLUDING CHRYSANTHEMUM ZAWADSKII EXTRACT

The present invention relates to a composition which is for preventing and ameliorating or treating premenstrual syndrome symptoms, and includes: (a) a Chrysanthemum zawadskii extract; (b) a mixture of the Chrysanthemum zawadskii extract and a malt extract; or (c) a mixture of the Chrysanthemum zawadskii extract, the malt extract, and an aloe extract. Specifically, the present compositions effectively inhibit the secretion of prolactin from pituitary cells, which is a phenomenon that appears during premenstrual syndrome, thereby increasing the secretion of progesterone, which is reduced during the luteal phase of women, and can thus be advantageously used as a composition for preventing and ameliorating or treating women's premenstrual syndrome.

COMPOSITIONS INCLUDING PIPERONYL BUTOXIDE AND PYRETHRUM EXTRACT
20220226417 · 2022-07-21 ·

In an embodiment, the present disclosure pertains to a lice-treating gel composition. In some embodiments, the composition includes piperonyl butoxide with a concentration from about 0.5 to 5 wt/wt %, pyrethrum with a concentration from about 0.1 to 1 wt/wt %, citronella with a concentration from about 0.1 to 1 wt/wt %, lemongrass oil with a concentration from about 0.01 to 0.5 wt/wt %, and tea tree oil with a concentration from about 0.01 to 0.5 wt/wt %. In an additional embodiment, the present disclosure pertains to a lice-treating gel composition including piperonyl butoxide with a concentration of about 3.889 wt/wt %, pyrethrins with a concentration of about 0.6 wt/wt %, citronella with a concentration of about 0.66 wt/wt %, lemongrass oil with a concentration of about 0.14 wt/wt %, and tea tree oil with a concentration of about 0.1 wt/wt %.

COMPOSITIONS INCLUDING PIPERONYL BUTOXIDE AND PYRETHRUM EXTRACT
20220226417 · 2022-07-21 ·

In an embodiment, the present disclosure pertains to a lice-treating gel composition. In some embodiments, the composition includes piperonyl butoxide with a concentration from about 0.5 to 5 wt/wt %, pyrethrum with a concentration from about 0.1 to 1 wt/wt %, citronella with a concentration from about 0.1 to 1 wt/wt %, lemongrass oil with a concentration from about 0.01 to 0.5 wt/wt %, and tea tree oil with a concentration from about 0.01 to 0.5 wt/wt %. In an additional embodiment, the present disclosure pertains to a lice-treating gel composition including piperonyl butoxide with a concentration of about 3.889 wt/wt %, pyrethrins with a concentration of about 0.6 wt/wt %, citronella with a concentration of about 0.66 wt/wt %, lemongrass oil with a concentration of about 0.14 wt/wt %, and tea tree oil with a concentration of about 0.1 wt/wt %.

COMPOSITIONS INCLUDING PIPERONYL BUTOXIDE AND PYRETHRUM EXTRACT
20220226417 · 2022-07-21 ·

In an embodiment, the present disclosure pertains to a lice-treating gel composition. In some embodiments, the composition includes piperonyl butoxide with a concentration from about 0.5 to 5 wt/wt %, pyrethrum with a concentration from about 0.1 to 1 wt/wt %, citronella with a concentration from about 0.1 to 1 wt/wt %, lemongrass oil with a concentration from about 0.01 to 0.5 wt/wt %, and tea tree oil with a concentration from about 0.01 to 0.5 wt/wt %. In an additional embodiment, the present disclosure pertains to a lice-treating gel composition including piperonyl butoxide with a concentration of about 3.889 wt/wt %, pyrethrins with a concentration of about 0.6 wt/wt %, citronella with a concentration of about 0.66 wt/wt %, lemongrass oil with a concentration of about 0.14 wt/wt %, and tea tree oil with a concentration of about 0.1 wt/wt %.

Total flavonoid extract from <i>Gynura formosana </i>Kitam., preparation method thereof, and use of same in treating non-alcoholic fatty liver disease

A total flavonoid extract from Gynura formosana Kitam., comprising 80-85% of rutin. A preparation method comprises selecting a complex enzyme consisting of a specific composition and ratio of enzymes for enzymatic hydrolysis, extracting and concentrating by a macroporous resin, and separating and purifying by a macroporous resin. The extract has therapeutic effect on non-alcoholic fatty liver disease.

Total flavonoid extract from <i>Gynura formosana </i>Kitam., preparation method thereof, and use of same in treating non-alcoholic fatty liver disease

A total flavonoid extract from Gynura formosana Kitam., comprising 80-85% of rutin. A preparation method comprises selecting a complex enzyme consisting of a specific composition and ratio of enzymes for enzymatic hydrolysis, extracting and concentrating by a macroporous resin, and separating and purifying by a macroporous resin. The extract has therapeutic effect on non-alcoholic fatty liver disease.